Related Experiment Video
Updated: Sep 12, 2026

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
Published on: August 16, 2016
Effects of lidocaine on myocardial function and on isoprenaline-induced circulatory changes in man
Abstract:
14 non-cardiac patients aged 42 to 71 years (mean 49 years) were studied. Part I 1 mg/kg or 2 mg/kg of lidocaine were administered i.v. on two consecutive days and systolic time intervals (STI) were obtained at one minute intervals for 30 minutes. No change in STI was observed after lidocaine injection. In Part II, a bolus of 5 mug of isoprenaline was given i.v. before and after an injection of 2 mg/kg of lidocaine. Isoprenaline caused a highly significant increase in the heart rate, shortening of the total electromechanical systole, pre-ejection period, electromechanical delay, isovolumic contraction time as well as PEP/LVET and ICT/QS1, indices (in all cases p less than 0.001). 2 mg/kg lidocaine had no blocking or potentiating action on the catecholamine-induced circulatory changes. In Part III, after the isoprenaline challenge, a dose of 2 mg/kg of lidocaine was administered and the bolus injection was followed by an infusion of 30 mug/kg/min. Lidocaine per se caused no change in STI in the course of the infusion over 90 minutes, and there was no difference between isoprenaline-induced changes in STI before and during lidocaine infusion. These results suggest that lidocaine has no negative inotropic effect in the therapeutic dose range in man. Lidocaine caused no change in the systolic time intervals, it had no blocking or potentiating action on the isoprenaline-induced circulatory changes, and it had no negative inotropic effect in therapeutic doses in man.
Related Concept Videos
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Heart Failure Drugs: Inotropic Agents
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Cardiopulmonary Resuscitation IV: Pharmacological Management

